Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
tiotropium pMDI · 1 trial · 1 indication
noncompartmental analysis
| Arm | Type | Description |
|---|---|---|
| Test Product 1 | EXPERIMENTAL | tiotropium pMDI 2 inhalations |
| Test Product 2 | EXPERIMENTAL | tiotropium pMDI 2 inhalations |
| Test Product 3 | EXPERIMENTAL | tiotropium pMDI 2 inhalations |
| Test Product 4 | EXPERIMENTAL | tiotropium pMDI 2 inhalations |
| Commercial Product | ACTIVE_COMPARATOR | tiotropium Respimat 2 inhalations |
| Name | Type | Description |
|---|---|---|
| tiotropium pMDI | DRUG | inhalation |
Inclusion Criteria: * Healthy Volunteer * Willing and able to give informed consent * Willing to withhold all alcoholic beverages for 48 hours and all xanthine- containing foods and beverages for 24 hours prior to reporting to clinic * Subjects must agree to use an adequate method of contraception ...
Tiotropium pMDI is an investigational small molecule being developed by Solventum Corporation (NYSE: SOLV). It is a metered-dose inhaler formulation of tiotropium. As of the available data, it is in early clinical development, having completed a Phase 1 trial in healthy volunteers.
Tiotropium pMDI is being studied in healthy volunteers. The completed clinical trial evaluated its pharmacokinetics compared to a reference product. Its use in specific disease conditions has not been established in the available data.
Tiotropium pMDI is being developed by Solventum Corporation, which trades on the New York Stock Exchange under the ticker SOLV. The company is conducting clinical research on this inhaled formulation of tiotropium.
Tiotropium pMDI is in Phase 1 clinical development. A single early Phase 1 trial has been completed. The drug is investigational and has not been approved by regulatory authorities.
Tiotropium pMDI has one completed clinical trial, NCT03155204, titled "Comparison of the Pharmacokinetics of Tiotropium Delivered From Test Inhaler Products With A Reference Product." This early Phase 1 study enrolled 46 healthy participants in the United Kingdom.
Tiotropium pMDI is a metered-dose inhaler formulation of the drug tiotropium. The clinical trial compared its pharmacokinetics to a reference tiotropium product. The pMDI designation refers to the specific delivery device used to administer the medication.